Clinical and histopathological analyses of VEGF receptors peptide vaccine in patients with primary glioblastoma - a case series

Table 3 Clinical results

Case No.	DTH	Vac cycles	Toxicity	ELISPOT (CTL)			CTL induction		PFS (days)	OS (days)	Evaluation after 12 M
Case No.	DTH	Vac cycles	Toxicity	timing	R1	R2	R1	R2	PFS (days)	OS (days)	Evaluation after 12 M
1	–	14	–	Before	N/A	N/A	N/A	N/A	554	967	PR
1	–	14	–	After	N/A	N/A	N/A	N/A	554	967	PR
2	–	14	–	Before	N/A	N/A	N/A	N/A	562	1272	SD
2	–	14	–	After	N/A	N/A	N/A	N/A	562	1272	SD
3	–	14	–	Before	–	+	+	+	–	Still survive (1425)	CR
3	–	14	–	After	+	3+	+	+	–	Still survive (1425)	CR
4	+	14	–	Before	–	N/A	+	+	–	Still survive (962)	CR
4	+	14	–	After	3+	2+	+	+	–	Still survive (962)	CR

CTL cytotoxic T lymphocyte, DTH delayed type hypersensitivity, M month, N/A not available, OS overall survival, PD progressive disease, PFS progression-free survival, PR partial response, R vascular endothelial growth factor receptor, SD stable disease, Vac vaccination

ISSN: 1471-2407